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Abstract
Background: Infection with respiratory pathogens can influence production as well as animal welfare. There is an
economical and ethical need to treat pigs that suffer from respiratory diseases. Our aim was the evaluation of the
possible effects of oral NSAID medication given in feed in acute outbreaks of respiratory disease in finishing pigs.
The short- and long-term impact of NSAID dosing on clinical signs, daily weight gain, blood parameters and behaviour
of growing pigs in herds with acute respiratory infections were evaluated. Four finishing pig farms suffering from acute
outbreaks of respiratory disease were visited thrice after outbreak onset (DAY 0, DAY 3 and DAY 30). Pigs with the most
severe clinical signs (N = 160) were selected as representative pigs for the herd condition. These pigs were blood
sampled, weighed, evaluated clinically and their behaviour was observed. After the first visit, half of the pens (five pigs
per pen in four pens totalling 20 representative pigs per herd, altogether 80 pigs in four herds) were treated with oral
ketoprofen (target dose 3 mg/kg) mixed in feed for three days and the other half (80 pigs) with a placebo. In three of
the herds, some pigs were treated also with antimicrobials, and in one herd the only pharmaceutical treatment was
ketoprofen or placebo.
Results: Compared to the placebo treatment, dosing of ketoprofen reduced sickness behaviour and lowered the rectal
temperature of the pigs. Clinical signs, feed intake or blood parameters were not different between the treatment
groups. Ketoprofen treatment was associated with somewhat reduced weight gain over the 30-day follow-up period.
Concentration analysis of the S- and R-enantiomers of ketoprofen in serum samples collected on DAY 3 indicated
successful oral drug administration.
Conclusions: Ketoprofen mainly influenced the behaviour of the pigs, while it had no effect on recovery from
respiratory clinical signs. However, the medication may have been started after the most severe clinical phase of the
respiratory disease was over, and this delay might complicate the evaluation of treatment effects. Possible negative
impact of ketoprofen on production parameters requires further evaluation.
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Background
Respiratory disease can influence production as well as
animal welfare [1, 2]. For example, acute infection by
one of the most common respiratory pathogens of pigs
in Finland, Actinobacillus pleuropneumoniae (APP) is
characterised by dyspnoea, cough, fever, reduced feed
and water intake [3] and changes in white blood cell
counts [3, 4].
Sickness behaviour is a consequence of inflammation.
Typical sickness behaviour in pigs includes lethargy,
reduced appetite, decreased motor activity and changes
in thermal regulation. These changes help to preserve
energy and to fight infection [5]. This response has been
examined in experimental challenge studies. For ex-
ample, pigs suffering from respiratory infection caused
by porcine reproductive and respiratory (PRRS) virus
spent more time lying in contact with another pig com-
pared with non-infected controls [2]. In addition,
PRRSv-inoculated pigs spent more time lying in ventral
position and in contact with a penmate and less time in
feeding compared to non-inoculated pigs [6].
Animals react to infections through an inflammatory
response involving elevated levels of acute phase
proteins in serum. In the pig, haptoglobin (Hp) is one of
the most extensively investigated acute phase proteins.
The concentration of Hp increases in serum within 48 h
after infection [7, 8]. Respiratory infections can induce
prominent increases in Hp levels as shown under experi-
mental [9, 10] and clinical conditions [11, 12]. Another
major acute phase protein in pig serum is amyloid A
(SAA), which has shown the biggest difference in mea-
sured values between non-infected vs. infected animals
of all investigated acute phase proteins [9, 13]. It has
been suggested that acute phase proteins could be used
as indicators of changes in animal health status or as
aids in clinical diagnosis during infections as they are
sensitive markers of infection [9].
There is an economical [14] and ethical need to treat
pigs that suffer from respiratory diseases. Often, anti-
microbial treatment is used. Recent evidence, however,
indicates that non-steroidal anti-inflammatory drugs
(NSAIDs) can also be beneficial in the treatment of
respiratory diseases in pigs. NSAIDs (especially ketopro-
fen) have been reported to have a good ability to reduce
fever [15–21] and at least to some extent to alleviate
clinical signs [15–18, 20–22]. However, significant effects
on blood parameters and growth have not been reported
[15, 20, 21]. Evidence of the effects of NSAIDs on sick-
ness behaviour is scarce and more information is
needed; one recent study reported favourable impact of
NSAID medication on sickness behaviour after lipopoly-
saccharide (LPS) administration [22].
The aim of our field study was to evaluate possible
effects of NSAID medication administered in feed to
finishing pigs during acute respiratory outbreaks in
clinical conditions. Medication mixed in feed would
be a practical alternative for medicating groups of
diseased pigs instead of labour-intensive individual
drug administration. However, sick animals usually eat
less and hence it is important to evaluate whether
medication mixed in feed could be successfully
employed. We followed the short- and long-time im-
pact of NSAID dosing on clinical signs, daily weight
gain, blood parameters, Hp and SAA concentrations
as well as on behaviour of pigs in groups of animals
suffering from an acute outbreak of respiratory infec-
tion. Our assumption was that ketoprofen given in
feed would alleviate clinical signs, reduce inflamma-
tion and decrease the behavioural effects of the
disease, hence, improve the welfare of pigs and their
daily weight gain.
Methods
This study was a randomised, double-blinded, placebo-
controlled clinical trial. It was also a substudy of a study
focusing on respiratory diseases in pigs in Finland
aiming to determine the main pathogens responsible for
acute respiratory diseases [23]. Local practicing veteri-
narians and farmers were asked to inform the research
group about acute outbreaks of respiratory clinical signs
in Finnish finishing pig herds during 2011–2014. The
herds were included in the bigger study according to the
same inclusion criteria that were applied for the current
substudy (see below).
In this study, clinical signs refer to signs detected dur-
ing a basic clinical examination, excluding behavioural
observations. Accordingly, by sickness behaviour we
mean observations regarding posture or activity of pigs,
as explained in the ethogram (see Table 1).
After the first notification of an acute outbreak of
respiratory disease, the research group personnel
contacted the farm and ensured that the farm and
the disease outbreak fulfilled the inclusion criteria:
1) the herd was rearing finishing pigs; 2) the herd
showed acute respiratory signs e.g. cough, lowered
appetite, apathy or mortality of animals; 3) the herd
had either feeding arrangements that allowed all pigs
in one pen to eat at the same time or automatic
feeding devices that allowed individual feeding and
medication for dosing of the oral medication; 4) the
location of the herd had to be close enough (within
250 km driving distance) to the university clinic
located in Mäntsälä, Southern Finland, for the re-
search team to be able to organise the sampling and
behavioural observations; and 5) the farmer was wil-
ling to participate. Altogether four farms were
eligible for study enrolment.
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Farm visits and data collection
A scheme depicting the study design containing the farm
visits, the treatment intervention and the numbers of
study animals is presented in Fig. 1. The research group
first visited the farm for a baseline visit (DAY 0) within
two days after the first notification of the acute outbreak.
The farm visit started approximately 3.5 h before the mid-
day feed was given to the pigs, allowing for behavioural
observations two hours prior to feeding. Researchers first
identified, after consulting the farm personnel, one com-
partment with the most profound clinical respiratory
signs. During the first farm visit (DAY 0), three pigs per
herd with acute respiratory clinical signs were selected for
euthanasia and pathological examination to discern the
pathogens involved in the outbreak. The lungs of these
pigs were chilled and transported to the laboratory
(Finnish Food Safety Authority Evira) for pathological,
virological and bacteriological investigations to be begun
on the next day.
From the selected compartment, eight pens containing
the pigs with the most severe clinical signs were in-
cluded in the study. Four pairs of two adjacent pens
sharing one feeding trough were selected on the three
farms using trough feeding. On the fourth farm using
automated individual feeders, eight pens in one room
were selected for sampling. Despite the shared trough,
pigs in adjacent pens could not restrict the pigs in the
other pen from approaching the feeding trough as there
was a solid fence between the adjacent pens. The study
pens housed an average of 11.3 (sd 1.4) pigs. From each
pen, five representative pigs for the herd condition
(altogether 40 pigs per farm) with the most severe cli-
nical signs were numbered on their backs with marking
spray from one to five. Half of the pens were randomly
allocated for ketoprofen administration and the other
half to the placebo treatment. Because of the shared
feeding troughs, the pair of adjacent pens was always
allocated to the same treatment. Each farm thus had 20
representative pigs divided into four pens receiving
ketoprofen and another 20 pigs in four pens serving as a
control group receiving treatment with placebo.
Two persons followed the behaviour of the representa-
tive pigs by direct observation with scan sampling every
five minutes for two hours before the midday feeding
equalling 24 observations per pig. The ethogram used is
presented in Table 1.
After behavioural follow-up, the same 40 animals were
evaluated clinically. Presence of clinical signs (YES/NO;
Table 1 The ethogram used in the behavioural analysis of
representative pigs in herds with respiratory disease outbreaks
BEHAVIOUR DEFINITION
Posture
Walk Moving all 4 legs.
Stand Standing on 4 legs motionless.
Sit Hindquarters touching floor.
Lie lateral Lying on either side.
Lie sternal Lying on the belly.
Lie alone Lying on side or belly, without contact to other pigs.
Activity
Active Head up, alert while lying, sitting or standing
(if cannot be identified as nosing, eating or drinking).
Eat Head in the trough
Drink Snout in contact with water nipple.
Nosing Touching pen mate or pen structures with snout
Passive Standing, sitting or lying motionless, head down,
not alert.
Other Invisible or none of the above.
Fig. 1 A scheme depicting the study design containing the farm visits, the treatment intervention and the numbers of study animals
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tear staining, tail bitten, and any other clinical sign) were
recorded. The farmer had been instructed to mark all
pigs with colour that were seen coughing on DAY 0 be-
fore the researchers arrived. In addition, all pigs that
were seen coughing during the farm visit in the selected
compartment were recorded as having a cough. Rectal
body temperature was measured and one EDTA and one
serum blood sample was taken from the vena jugularis
after catching the pig with a snout snare. An ear mark
with an individual number was attached to the ear of
these 40 pigs. Finally, each of these 40 pigs was weighed.
Unfortunately, the scale used at farm #4 turned out to
be unreliable and weighing results from this farm had to
be discarded. Also, approximately half of DAY 30
weighing results from farm #1 are missing because of
human error.
The second farm visit was carried out three days later
(DAY 3). Behavioural and clinical evaluations were
repeated, and the pigs were weighed, and blood was
sampled (EDTA and serum samples). About 30 days
(range 21–34 days) later (DAY 30), the farm was visited
for the third time. The same pigs were evaluated clini-
cally and weighed, and blood was sampled (only serum).
Unfortunately, the data recordings made during the
third farm visits were incomplete regarding clinical
signs, leading to many missing values in the data.
Medication
All pigs in the same pens with the representative pigs
were given either ketoprofen 3 mg/kg or a placebo per
os once a day for three days starting in the morning of
DAY 1. The doses were calculated according to the
number and weighing results of the representative pigs
and the visually estimated weights of the rest of the pigs
in each pen. The daily medications for each pen were
dosed in small plastic bags. Herds 1–3 had long troughs,
where all pigs fit to eat simultaneously. The farmers of
these herds were instructed to mix the medication with
small amounts (5–10 l) of regular pig feed and give the
mixture by hand into the feeding trough once a day be-
fore the morning feeding. The farmer was instructed to
follow the feeding during medication days and register
any pigs that did not eat normally. In herd 4, the daily
dose was given to the pigs through a sophisticated auto-
mated feeding system. Each pen had an automatic
feeder, which identified each individual pig by its trans-
ponder device and delivered individual daily feed rations
in several small portions during the day. The feeder had
a dispenser capable of measuring small amounts of feed
components. The dispenser measured, mixed and dosed
the ketoprofen or placebo medication for each pig in the
first feed portion in the morning. The feeder also
measured the amount of feed eaten by each individual
pig during the whole day.
The researchers had no possibility of deciding the anti-
microbial medication given to the affected animals; only
ketoprofen and placebo could be added in each herd. In
herd #1, all pigs were treated with intramuscular injec-
tions of long-acting tetracycline (20 mg/kg) on DAYs 0, 2
and 4. In herd #2, intramuscular tetracycline injections
(10 mg/kg) were given daily for 5 days to the pigs with
clinical signs of respiratory disease. Unfortunately, the
farmer had no exact records of the treated animals, but
approximately 30% of all pigs in the room were treated
and most of the representative pigs were likely to be in-
cluded in the group of animals receiving tetracycline. In
herd #3, all pigs were given intramuscular injections of
tetracycline 3 and 1 days before the first farm visit (DAYs
− 1 and − 3) and the treatment was continued per os
(20 mg/kg) starting on DAY -1 for five days. In herd #4,
no antibiotics were used because of mild clinical signs.
Laboratory analyses
Blood samples were transported to the laboratory during
the day of the farm visits and centrifuged (3000 rpm,
10 min) there. The sera were stored at − 18 °C until
analysis. The EDTA samples were investigated on the day
of sampling. The haemoglobin concentration (HGB),
haematocrit (HCR), red blood cell count (RBC), white
blood cell count (WBC), and platelet count (PLT) were
measured for samples taken on DAY 0 and DAY 3 using
an Animal Blood Counter Veterinary machine (ABX
Diagnostics, Montpellier, France) in the Saari Laboratory,
Faculty of Veterinary Medicine, Department of Production
Animal Medicine, University of Helsinki.
For aerobic pathogen detection, the lung tissue
samples were cultivated on bovine blood agar and incu-
bated at 37 °C. In addition, for possible APP biotype 1
and Haemophilus parasuis isolation, the samples were
cultivated on bovine blood agar with a Staphylococcus
aureus streak and incubated under a 5% CO2 atmos-
phere at 37 °C. The small colonies showing enhanced
growth around the S. aureus streak were isolated and
confirmed by a positive Camp reaction. They were tested
using multiplex PCR, which identified the species and
APP serotypes 2, 5 and 6. The non-haemolytic NAD-
dependent isolates with a negative CAMP reaction were
further tested for Haemophilus parasuis using biochem-
ical tests (oxidase, catalase, urease, fermentation of
xylose, mannitol, inulin, trehalose and xylose supple-
mented with NAD and horse serum).
Serum Hp was analysed from samples taken on DAY
0, 3 and 30 using a modified haemoglobin-binding assay
developed for cows [24], in which tetramethylbenzidine
was used as a substrate [25] and 5 μl of sample volume
(originally 20 μl). The assay was adapted for microtitra-
tion plates and optical densities of the wells were read at
450 nm using a spectrophotometer (Multiskan MS,
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Labsystems Oy, Vantaa, Finland). Pooled and lyophilized
aliquots of porcine acute phase serum were used to
create standard curves by serial dilutions. The standard
curve range was 181–2900 mg/L. Samples with higher
results than the standard range were diluted and re-
assayed. The assay was calibrated using a porcine serum
sample of known Hp concentration provided by the
European Commission Concerted Action Project
(number QLK5-CT-1999-0153). Serum SAA was analysed
from samples taken on DAY 0, 3 and 30 with a commer-
cial sandwich ELISA according to the manufacturer’s in-
structions for porcine serum (Phase SAA assay, Tridelta
Development Ltd., Maynooth, Co. Kildare, Ireland).
Serum concentrations of both ketoprofen enantio-
mers (S- and R-ketoprofen) were determined for all
DAY 3 samples from animals in the ketoprofen treat-
ment group. In addition, eight samples taken on day
0 (before treatment) and eight from DAY 3 from the
placebo-treated animals were analysed. Chiral high-
performance liquid chromatography (HPLC) combined
with UV detection was used for the quantitative ana-
lysis of ketoprofen enantiomers in pig serum. The
analysis method was modified from a previously
published description [26]. Samples were prepared by
mixing 300 μl of serum, 50 μl of internal standard so-
lution (S-(+)-naproxen, 100 μg/ml) and 650 μl of
0.4% formic acid in water:propanol (96:4). Solid-phase
extraction cartridges were conditioned with 1.2 ml of
1% acetic acid in propanol and 1 ml of water.
Samples (1 ml) were passed through the cartridges,
which were then washed with 1.5 ml of 0.4% formic
acid in water:propanol (96:4), followed by 1 ml of
water. Solutes were eluted with 1.2 ml of 1% acetic
acid in propanol. The solvent was evaporated to
dryness in a stream of nitrogen. The residue was
redissolved in mobile phase A and transferred into
autosampler vials for HPLC analysis. The chromatog-
raphy system consisted of a Waters Alliance 2695
Separations module and a Waters 2487 Dual λ
absorbance detector. The analytical column was an
Ultron ES-OVM chiral column (4.6 × 150 mm) pre-
ceded by a Ultron ES-OVM chiral guard column
(4.0 × 10 mm), both from Shinwa Chemical Industries
Ltd. (Kyoto, Japan). The mobile phase was an iso-
cratic mixture of A: 16 mM phosphate buffer
(pH 3.0) and B: acetonitrile (93:7). The flow rate was
1.0 ml/min. The UV detector was set at 254 nm. The
chromatograms were processed using Empower 3
software (Waters). The linear concentration range was
from 0.1 μg/ml to 20.0 μg/ml. Calibration curves were
weighted by 1/x2 and yielded coefficients of determin-
ation (R2) of 0,997–1000 and 0,997–0,999 for S-keto-
profen and R-ketoprofen. The inter-assay accuracy of
the quality control samples (at three different
concentration levels, 0.3, 7.5 and 15.0 μg/ml) ranged
from 94.9% to 104.4% for S-ketoprofen and from
94.1% to 103.7% for R-ketoprofen.
The samples from the 15 pigs (out of 20 sampled
animals) having paired serum samples available after
sample taking and processing, in sampling order, both
from DAY 0 and DAY 30 were used for APP
serology. APP antibodies were measured using two
commercial test kits: IDEXX APP-ApxIV ELISA
(IDEXX, Liebefeld-Bern, Switzerland) to detect anti-
bodies against ApxIV toxin, which is produced by all
known APP serotypes and IDvet ID Screen APP 2
indirect ELISA (IDvet, Grabels, France) to detect anti-
bodies against LPS specific to APP serotype 2. Both
tests were performed according to the manufacturer’s
instructions. The absorbance results were interpreted
as negative or unclear (score 0), or positive with
scores ranging from 1 to 5. Seroconversion was
defined as an increase in the score by at least one
number, e.g. from negative to 1, or from 3 to 4, be-
tween DAY 0 and DAY 30. If both the first and the
second sample showed the highest antibody level 5,
the pig was also defined as seroconverted.
Similarly, the 15 animals from each herd having
paired sera available from DAY 0 and DAY 30 were
used for SIV serology. All blood samples were tested
with influenza A antibody ELISA (ID Screen® Influ-
enza A Antibody Competition, IdVet, Grabels, France)
according to the instructions of the kit manufacturer.
If at least one pig tested unclear or positive in
influenza A ELISA on DAY 0 or 30, blood samples of
that herd were further analysed using a haemagglutin-
ation inhibition (HI) test according to the operating
procedure of the European Surveillance of Influenza
in Swine with the antigens H1N1 (SW/Best/96),
H1N2 (SW/Gent/7625/99) and H3N2 (SW/St.
Oedenrode/96). All the antigens were provided by GD
Animal Health Service (Deventer, NL). A sample was
considered HI positive if the HI titre was ≥1:20. Sero-
conversion was defined as an increase in the HI titre
between DAY 0 and DAY 30.
Statistical analysis
A required sample size of 80 pigs per group was
calculated for the main outcome (daily weight gain) with
power 0.8 and confidence level 0.95 assuming equal vari-
ances and adjusted for clustering at pen level (assuming
cluster size 11, intra cluster correlation 0.1 and coeffi-
cient of variation of cluster sizes of 0.1) and assuming a
100-g difference in daily weight gain between the
treatment groups.
Descriptive statistics were calculated for daily weight
gain, blood parameters, concentrations of S- and R-keto-
profen and for clinical signs and behaviour. An animal
Hälli et al. Porcine Health Management  (2018) 4:7 Page 5 of 14
was used as the observational unit and results are pre-
sented as means and standard deviations (sd) for both
treatment groups for all other data except behavioural
variables. Mean occurrence (as a proportion of a total of
24 observations per pig) of each behaviour of the five
pigs in each pen per observation day were calculated
and pen mean was used in the statistical analyses. Be-
cause of different baseline levels of body temperature,
weight, Hp and SAA concentrations on DAY 0 between
the treatment groups, the changes in these variables be-
tween DAY 0 vs. DAY 3 within each treatment group
were calculated by subtracting the value on DAY 0 from
the value on DAY 3.
Descriptive statistics were compared within the
treatment groups (ketoprofen/placebo) across different
days by paired t-tests for body temperature, all blood pa-
rameters (except SAA values), weight and daily weight
gain, by McNemar’s test for clinical signs, by a repeated
measures general linear model for differences in beha-
vioural variables, including farm as a fixed factor, and by
Wilcoxon’s signed rank non-parametric test for SAA
values. Effect of treatment on the magnitude of change
in behaviour was tested with univariate models,
including farm as fixed factor.
Drinking behaviour was very rare as was also ‘other
behaviour´. These parameters were therefore not in-
cluded when analysing the data. Due to technical errors
during the observations, no records for activities were
available for two of the pens on one farm.
Crude associations between outcome variables and
treatment (ketoprofen/placebo) and other explanatory
variables (sex) were evaluated using a liberal p-value
(0.2) or strong suspicion of biological causal connection.
Linear regression was used for that purpose for daily
weight gain, body temperature and blood parameters
excluding SAA values on DAY 0 and 3. Wilcoxon rank-
sum non-parametric testing was used for SAA values on
DAY 0 and 3. Logistic regression was used for variables
related to clinical signs. Crude associations were not
tested for behavioural variables.
Finally, multivariate models were built for the variables
evaluated as significant in the crude association analysis
and for the behavioural variables. A multilevel mixed-
effects linear regression model was fitted for the out-
comes weight and daily weigth gain, body temperature
and change in body temperature as well as for the Hp
and change in Hp and SAA concentrations, containing
pen and farm as random intercepts and treatment and
sex as fixed effects. Use of antimicrobial treatment in
the herd to manage this respiratory outbreak (yes/no)
was included as a fixed effect in the multilevel mixed-
effects linear regression models for daily weight gain
from DAY 0 to DAY 30 and for body temperature for
DAY 3. In all other models, antimicrobial treatment did
not remain significant and did not act as a confounder.
A repeated measures general linear model with treat-
ment and farm as fixed factors was fitted for behaviour
variables. Because of marked variability of actualized
interval of DAY 0 and DAY 30 herd visits, the number
of days between the first and third herd visits was in-
cluded in appropriate models. The level of significance
was set to 0.05.
For brief model diagnostics, the basic assumptions of
linear models were inspected with regard to the data
structure and nature of the outcome variables. In
addition, residuals were scrutinized. No serious breaches
of the underlying assumptions were detected.
The results for Hp and SAA regarding third blood
sampling (DAY 30) are presented only in the annex. The
serum blood sample on DAY 30 was mainly taken for
serology and acute phase proteins were analysed as the
samples were readily available. However, it is unlikely
that the ketoprofen medication used on DAY 1–3 had
any effect on acute phase proteins on DAY 30.
Statistical analysis for all other outcomes than be-
haviour was made with STATA 14.2 program and the
analysis of behavioural data was made with SPSS 21
statistical software.
Results
Data consisted of 160 representative pigs for the herd
condition from four farms: 75 (46.9%) castrated boars,
20 (20.5%) intact boars and 65 (40.6%) gilts, altogether
80 finishers in both the ketoprofen and placebo groups.
In three herds, there were only castrated boars and fe-
males, which were distributed evenly in each herd. Intact
boars were present on one farm, where they constituted
half of the animals. All three sexes were divided evenly
between the ketoprofen and placebo groups.
Behaviour analysis
The results of the behavioural data for different treat-
ment groups are presented in Table 2. Several beha-
vioural differences are presented in the ketoprofen-
treated pigs on DAY 3 as compared to DAY 0 based on
repeated measures general linear model. On DAY 3, they
were observed to stand, walk and lie more often on ster-
num and less often on flank and more often alone (not
in contact with other pigs) than on DAY 0. In addition,
the ketoprofen-treated pigs were more active and
showed more nosing on DAY 3. Correspondingly, fewer
observations of passive behaviour were recorded on
DAY 3. In the placebo-treated pigs, the only observed
change in behaviour from DAY 0 to DAY 3 was a de-
crease in lying on sternum. Figure 2a and b present the
magnitude of these changes in the ketoprofen- and
placebo-treated pigs.
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Clinical signs and rectal temperature
The summary of clinical signs and rectal temperature of
study animals during the clinical examination is
presented in Table 3. Within the groups, the body
temperature and number of coughing pigs decreased in
both the ketoprofen- and placebo-treated pigs from the
time of acute disease towards the end of the study when
animals recovered from clinical disease. There was no
treatment effect on any clinical signs based on results
from single variable logistic regression models.
According to the mixed model, rectal temperature
tended to be somewhat lower (by 0.23 °C) on DAY 0 in
the placebo group compared to the ketoprofen-treated
group (p = 0.07). On DAY 3, pigs receiving the placebo
had significantly higher (by 0.26 °C) rectal temperature
than those treated with ketoprofen (p = 0.01). The pigs
in the three herds with antimicrobial treatment did have
0.4 °C lower body temperature on DAY 3 than the pigs
in the herd not receiving antibiotic treatment (p < 0.01).
No difference was detected in body temperature on
DAY 30. The rectal temperature change from DAY 0 to
DAY 3 was affected by the ketoprofen treatment (p <
0.001). The body temperature of the placebo-treated pigs
decreased less (on the average by 0.3 °C from DAY 0 to
DAY 3) than that of ketoprofen-treated pigs (by 0.8 °C).
There was no difference in temperature change between
DAY 0 and 30 between the treatment groups.
Acute phase proteins
Haptoglobin serum concentrations were measured for 77
ketoprofen-treated animals on DAY 0 and 75 for DAY 3
and for placebo-treated animals 79 and 77, respectively.
Serum amyloid A concentrations were measured for 77
ketoprofen-treated animals on DAY 0 and 75 for DAY 3
and for placebo-treated animals 79 and 78, respectively.
Hp serum concentrations were higher on DAY 0
compared to DAY 3 in both treatment groups (p < 0.01
for ketoprofen group and p = 0.01 for placebo group).
Based on a mixed model, there was no difference in Hp
concentrations between the treatment groups before
treatment (DAY 0). The treatment was associated with
Hp levels on DAY 3. Pigs in the placebo group had, on
the average, 268 mg/l higher haptoglobin concentrations
in serum than the pigs in the ketoprofen-treated group
(p = 0.01). The Hp concentration change from DAY 0 to
DAY 3 (calculated by subtracting Hp on DAY 0 from Hp
on DAY 3) was not associated with the treatment.
Table 2 Behaviour of representative pigs in a group having a respiratory infection presented as proportion of observations mean ±
sd out of 24 observations in two hours before treatment (DAY 0) and on the last day of treatment (DAY 3). The pigs were given
ketoprofen or placebo on DAY 1–3
Behaviour Treatment group N of pens DAY 0 Mean ± sd N of pens DAY 3 Mean ± sd
Lie flank Placebo 16 0.32 ± 0.17A 16 0.37 ± 0.12A
Ketoprofen 16 0.43 ± 0.19a,B 16 0.23 ± 0.11b,B
Lie sternum Placebo 16 0.52 ± 0.17a 16 0.44 ± 0.11b,A
Ketoprofen 16 0.43 ± 0.13a 16 0.51 ± 0.10b,B
Sit Placebo 16 0.03 ± 0.02 16 0.04 ± 0.02
Ketoprofen 16 0.02 ± 0.02 16 0.03 ± 0.02
Stand Placebo 16 0.09 ± 0.07 16 0.10 ± 0.05A
Ketoprofen 16 0.09 ± 0.08a 16 0.17 ± 0.08b,B
Walk Placebo 16 0.04 ± 0.01 16 0.05 ± 0.05
Ketoprofen 16 0.03 ± 0.03a 16 0.07 ± 0.04b
Lie alone Placebo 16 0.09 ± 0.09 16 0.09 ± 0.06
Ketoprofen 16 0.09 ± 0.10a 16 0.14 ± 0.11b
Active Placebo 14 0.16 ± 0.10 14 0.20 ± 0.16
Ketoprofen 14 0.11 ± 0.09a 14 0.21 ± 0.14b
Passive Placebo 14 0.69 ± 0.14 14 0.67 ± 0.16
Ketoprofen 14 0.80 ± 0.16a 14 0.60 ± 0.13b
Eat Placebo 14 0.03 ± 0.03 14 0.03 ± 0.02
Ketoprofen 14 0.03 ± 0.03 14 0.04 ± 0.04
Nosing Placebo 14 0.10 ± 0.07 14 0.10 ± 0.07A
Ketoprofen 14 0.05 ± 0.06a 14 0.15 ± 0.11b,B
a,bValues with different superscripts within the same row differ significantly, p ≤ 0.05
A,B Values with different superscripts within the same column differ significantly, p ≤ 0.05
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Figure 3 presents Hp concentrations of pigs in the keto-
profen- and placebo-treated groups.
SAA concentrations were higher on DAY 0 compared to
DAY 3 in both treatment groups (p < 0.01 for both treatment
groups). Based on Wilcoxon’s rank-sum non-parametric test,
there was no statistically significant difference between the
treatment groups in SAA concentrations on DAY 0 or
DAY3. The SAA concentration change from DAY 0 to DAY
3 (calculated by subtracting SAA on DAY 0 from SAA on
DAY 3) was not affected by the treatment. Figure 4 presents
SAA concentrations of pigs in both groups.
Clinical blood parameters
Table 4 contains detailed results for complete blood
count parameters. Treatment was not associated with
any of the blood parameters analysed.
Body weight, daily weight gain
The farmers reported three (2.5%) animals that did not
eat normally during the medication days on the three
farms having long troughs. On the fourth farm with the
automated feeding system measuring the amount of feed
eaten by each individual pig, all pigs included in the
study ate the medicated feed portion by noon. The pigs
in the placebo and ketoprofen groups ate similar and
increasing amounts of feed from DAY 0 to DAY 3 on
this farm.
Body weights were not statistically significantly differ-
ent between the treatment groups on DAY 0 or DAY 3,
even if the pigs in the placebo group tended to be some-
what lighter than those receiving ketoprofen. Based on
mixed model, daily weight gain between DAY 0–3 was
not significantly associated with the treatment, but pigs
in the placebo group showed better daily weight gain (by
104 g per day) from DAY 0 to DAY 30 (p = 0.01) than
the ketoprofen group. The pigs in the herds with anti-
microbial treatment had 169 g less daily weight gain
from DAY 0 to DAY 30 compared to the pigs in the
herd not receiving antimicrobials (p = 0.01). However,
antimicrobial treatment did not confound the ketoprofen
treatment effect during the same time period. Table 5
shows all body weight-related results.
Ketoprofen concentrations
No samples collected from the placebo-treated pigs or
collected from the ketoprofen-treated pigs before treat-
ment start (baseline samples) contained detectable
amounts of S- or R-ketoprofen. Serum S-ketoprofen
concentrations were above the validated lower limit of
quantification (LLOQ; 0.1 μg/ml) in 76 out of the 79
(96%) samples taken from ketoprofen-treated pigs on
the last day of treatment. The remaining three pigs had
serum S-ketoprofen concentrations just below the
LLOQ. For R-ketoprofen, serum concentrations were
above the LLOQ in 47 samples (60%). The mean (+sd)
serum concentrations of S- and R-ketoprofen on DAY 3
were 1.41 ± 1.58 and 0.22 ± 0.20 μg/ml. The concentra-
tion frequency distributions of S- and R-ketoprofen on
DAY 3 are presented in Fig. 5a and b. The blood samples
for ketoprofen analysis were taken on DAY 3, on the
average 324 ± 35 min after administration of the
medicine mixed in feed.
Pathogens involved in the respiratory infection
Based on the results from the autopsies and serology, all
herds had an acute respiratory outbreak caused by APP
and in one herd, also swine influenza virus may have
been involved. At least one pig out of three autopsied
per herd revealed an acute lung infection, where APP
could be cultured and diagnosed as APP serotype 2. No
other APP serotypes were discovered. In one individual
a
b
Fig. 2 a Difference in mean (± sd) occurrence (as a proportion of a
total of 24 observations per representative pig) of postures between
DAY 0 and DAY 3. The pigs were given oral ketoprofen or placebo on
DAY 1–3. Asterisks above bars indicate a significant difference in the
magnitude of the change between placebo and ketoprofen pigs (*
p < 0.05, *** p < 0.001). b Difference in mean (±sd) occurrence (as a
proportion of a total of 24 observations per representative pig) of lying
alone and behavioural activities between DAY 0 and DAY 3. The pigs
were given oral ketoprofen or placebo on DAY 1–3. Asterisks above
bars indicate a significant difference in the magnitude of the change
between placebo and ketoprofen pigs (* p < 0.05, *** p < 0.001)
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animal, the pathological examination showed a mixed
bacterial infection, where in addition to APP, Pasteurella
multocida could be cultured. None of the autopsies
revealed signs of other respiratory pathogens.
All four herds had pigs with seroconversion of APP
antibodies in their paired serum samples. On the aver-
age, 67% and 45% of the pigs seroconverted between
DAY 0 and DAY 30 based on either ApxIV toxin or
APP2 LPS serological tests. In addition, in one herd,
13% of the animals had rising antibodies against SIV in
their paired samples between DAY 0 and DAY 30.
Discussion
The aim was to evaluate possible effects of NSAID
medication administered in feed to finishing pigs during
acute respiratory disease outbreaks in field conditions.
Drug exposure was documented by concentration ana-
lysis in serum. Ketoprofen had the expected antipyretic
effect and reduced behavioural signs of sickness.
However, no statistically significant differences were
noted between the ketoprofen- and placebo-treated ani-
mals in clinical signs, short-term weight gain or blood
parameters. Unexpectedly, the animals of the placebo
group showed better daily weight gain during the 30-day
observation period after the medication than the
ketoprofen-treated animals.
Behaviour
The increase in activity and postures related to higher
activity levels (standing, walking, lying on sternum) of
the ketoprofen-treated pigs on DAY 3 compared to
Fig. 3 Haptoglobin concentrations (mg/l, mean and sd) for finishing
pigs in herds having a respiratory disease outbreak. The pigs were
given oral ketoprofen during DAY 1–3 and sampled before
treatment (DAY 0) and on the last day of treatment (DAY 3). Bars
marked with different letters (A, B) differ significantly from each
other (p < 0.05), the comparison is valid only within treatment
group (ketoprofen/placebo)
Table 3 Summary of clinical signs and rectal temperature of representative pigs in a group with respiratory infection
DAY 0 DAY 3 DAY 30
Variable Treatment group
N N (%) of animals N N (%) of animals N N (%) of animals
Cough Placebo 80 9 (11.3)a 80 0 (0)b 50 0 (0)b
Ketoprofen 80 7 (8.8)a 79 0 (0)b 50 0 (0)
Tear staining Placebo 80 41 (51.2) 80 46 (56.3) 50 29 (58)
Ketoprofen 80 42 (52.5) 79 42 (53.2) 50 34 (68)
Bitten tail Placebo 80 20 (25) 80 13 (16.3)b 50 15 (30)c







Rectal temperature Placebo 80 39.8 ± 0.6a 80 39.4 ± 0.4b,A 80 39.3 ± 0.2b
Ketoprofen 80 40.0 ± 0.8a 80 39.1 ± 0.4b,B 80 39.3 ± 0.3c
Pigs were given oral ketoprofen (3 mg/day) or a placebo during DAY 1–3. The clinical inspections were performed before treatment (DAY 0), on the last day of
treatment (DAY 3) and on DAY 30
a,b,cValues with different superscripts within the same row differ significantly, p ≤ 0.05
A,BValues with different superscripts within the same column differ significantly, p = 0.01
Fig. 4 Serum amyloid A concentrations (mg/l, mean and sd) for
finishing pigs in herds with a respiratory disease outbreak. The pigs
were given oral ketoprofen or placebo during DAY 1–3 and sampled
before treatment (DAY 0), on the last day of treatment (DAY 3) and
on DAY 30. Bars marked with different letters differ significantly from
each other (p < 0.01)
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DAY 0 all indicate a decrease in behavioural signs of
sickness [27], which was not apparent in the placebo-
treated pigs. In our study, the pigs had only mild
clinical signs and none of the animals was clearly dys-
pnoeic. Thus, we did not interpret sitting, or lying in
a sternal position to be signs of pigs trying to ease
their respiration. Instead, we interpreted lying in a
sternal position as a sign of a more active behaviour
compared to lying on the flank, which was further
supported in the ketoprofen-treated pigs by increased
nosing, which is a form of exploratory behaviour. Ex-
ploration has been reported to be reduced as a result
of sickness [27]. The increase in lying alone in the
ketoprofen group was interpreted as a sign of im-
proved control of body temperature, as pigs are
known to huddle when they experience a colder am-
bient temperature.
The only observed difference in frequency of beha-
viours on DAY 0 between treatment groups was in the
lying in a flank position. We are unable to give any
causal explanation for this difference. We suppose it to
be coincidental especially because any other behaviours
did not have baseline differences.
Altogether, the behavioural changes reported here
are in line with changes seen in pigs experimentally
infected with viral respiratory disease [2, 6]. Recently,
ketoprofen has been shown to prevent the develop-
ment of sickness behaviour, including depression
caused by lipopolysaccharide-induced inflammation,
which is in agreement with the observed higher acti-
vity levels observed in the current study [22].
Clinical signs and rectal temperature
Before treatment, both groups had elevated rectal tem-
peratures because they had been suffering from an acute
respiratory infection for one or two days. On the last
day of treatment, the body temperature had gone down
in both treatment groups. The decline was, however,
more pronounced in the ketoprofen group. This effect is
understandable as ketoprofen has a good antipyretic ef-
fect in swine given in drinking water [15]. We show here
that an antipyretic effect can also be achieved by giving
ketoprofen in feed in clinical conditions.
We did not observe a treatment effect on any clin-
ical signs (cough, tear staining, bitten tail) evaluated.
Most previous studies reported an improvement in
clinical signs on NSAID treated animals compared to
the non-treated controls suffering from respiratory in-
fection [14, 15]. In our study, some animals had
already been treated with antimicrobial agents before
the first visit, which may have lowered the severity of
the clinical signs and made the possible differences in
clinical signs pre- and post-medication smaller and
thus less likely to be detected. Respiratory disease
outbreaks were quite mild, as approximately only 10%
of study pigs were coughing before the treatment.
Furthermore, none of the pigs were coughing any
longer at the second and third study visits, and dys-
pnea was not observed during the whole study period,
which confirms the acute nature of the clinical re-
spiratory disease in our study herds. On the other
Table 5 Body weight and daily weight gain of representative pigs in a group of finishing pigs with respiratory clinical signs






Body weight, kg Placebo 60 40.1 ± 7.1a 60 43.1 ± 7.5a 50 70.9 ± 9.5b
Ketoprofen 60 43.4 ± 8.8a 60 46.3 ± 9.1a 50 71.1 ± 12.2b
DAY0-DAY 3 DAY 0-DAY 30
Daily weight gain, g Placebo 60 1046 ± 719 50 992.5 ± 145A
Ketoprofen 60 1235 ± 721 a 50 886.8 ± 197b,B
The pigs were given oral ketoprofen (3 mg/kg) or placebo during DAY 1–3 and weighed before treatment (DAY 0), on the last day of treatment (DAY 3) and on
DAY 30
a,bValues with different superscripts within the same row differ significantly, p ≤ 0.05
A,BValues with different superscripts within the same column differ significantly, p = 0.01
Table 4 Clinical blood parameters (mean and standard
deviation, sd) of representative pigs in a group of finishing pigs
with respiratory clinical signs
Variable Treatment group DAY 0 DAY 3
N (Mean ± sd) N (Mean ± sd)
WBC (109) Placebo 74 24.4 ± 6.4 74 25.1 ± 6.3
Ketoprofen 75 23.1 ± 5.6 78 23.9 ± 5.3
HB (g/l) Placebo 74 112.6 ± 10.0 74 110.9 ± 11.1
Ketoprofen 75 110.5 ± 12.1 78 112.0 ± 11.0
HCT (%) Placebo 74 34.5 ± 4.5 74 34.6 ± 3.9
Ketoprofen 75 34.5 ± 4.2 78 34.7 ± 3.7
PLT (1000/μl) Placebo 74 394.8 ± 127.3 74 411.6 ± 112.3
Ketoprofen 75 368.0 ± 115.3a 78 414.3 ± 90.2b
The pigs were given oral ketoprofen (3 mg/kg) or placebo during DAY 1–3
and sampled before treatment (DAY 0) and on the last day of treatment
(DAY 3)
White blood cell count =WBC, haemoglobin = HG, haematocrit = HCT,
platelet count = PLT
a,bValues with different superscripts within the same row differ
significantly, p ≤ 0.05
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hand, as all pigs recovered swiftly, it may be that we
missed the most acute phase of the disease episode.
In case of an acute respiratory disease, the time
elapsed after the beginning of the outbreak and the
first herd visit may have been too long.
There were numerous missing values in the data re-
garding the clinical observations made on DAY 30,
which may have led to observation bias. However, the
missing values were distributed evenly to all herds and
both treatment groups, which makes this bias unlikely.
Haptoglobin and serum amyloid a
Regardless the treatment group, serum Hp concentration
was elevated on DAY 0 compared to DAY 3 or DAY 30.
Our samples were taken approximately two and five days
post infection, even though there might be notable vari-
ation as we do not know the exact day of onset of clinical
signs. As Hp reaches its peak concentration 2–3 days post
infection and stays elevated up to 7 or more days post in-
fection [10, 13, 28] it is likely that we had a good chance to
detect elevated Hp serum concentrations. On all three
sampling days, the Hp concentrations in both treatment
groups were higher than the reference range (10–1310 mg/
l) measured in a healthy boar herd [29]. A very similar
range of Hp concentrations (2000–4000 mg/l) has been re-
ported in pigs experimentally infected with APP or swine
influenza virus [10, 13] and in pigs infected with several re-
spiratory pathogens in clinical conditions [11]. However, it
should be kept in mind that Hp concentration variation be-
tween herds could be notable depending on the overall
health status and management of the herd, and Hp concen-
tration comparisons between farms may not be very in-
formative [30–32]. The magnitude of change in Hp
concentrations from DAY 0 to DAY 3 was not affected by
the treatment. Similar results of NSAID having no effect on
Hp levels in endotoxin-challenged pigs have been obtained
earlier [20].
SAA concentrations measured in specific pathogen free
pigs are usually below 15 mg/l [11]. Compared to this refer-
ence value, SAA concentrations in this study before treat-
ment in both treatment groups was clearly elevated and
indicative of a positive acute phase response. Infected ani-
mals reach peak SAA concentrations within 1–2 days post
infection and SAA seems to remain elevated at least 4 days
post infection [10, 13, 28]. Our observed concentrations
were in a similar range (40–60 mg/l) as those in swine in-
fluenza virus (SIV) infected pigs two days post infection
[29]. In pigs experimentally infected with APP, even higher
SAA concentrations (400–600 mg/l) were found 2–4 days
post infection [10]. In co-infection with SIV and Pasteurella
multocida, the peak level of SAA was observed as 155 μg/
ml [13]. We did not find an effect of ketoprofen on SAA
levels in pigs suffering from respiratory infection. Unfortu-
nately, there is no previous knowledge regarding the effect
of ketoprofen on SAA levels in infected pigs. In young
calves, ketoprofen alone is able to decrease SAA concentra-
tions after lipopolysaccaride challenge [33]. As the observed
difference between the treatment groups in the change in
SAA values from DAY 0 to DAY 3 was substantial, it might
be that our study lacked sufficient power to detect a statisti-
cally significant treatment effect.
Other blood parameters
The white blood cell count (WBC) was slightly elevated
on DAY 0 and DAY 3 in pigs in both treatment groups
compared to species specific reference values [34]. All
other blood parameters in study pigs were within normal
limits, as expected. There was no treatment effect on
WBC which is in agreement with an older study where
pigs were infected with APP [3]. The lack of treatment
effect may be due to the overall mild clinical signs
observed. On the other hand, very little is known about
WBC alterations in pigs during respiratory disease or as-
sociated with NSAID treatment. It might be that they
are not very sensitive markers of infection or
Fig. 5 a Serum S-ketoprofen concentration frequency distribution
(μg/ml) in samples (n = 79) taken on DAY 3 in ketoprofen treated
finishing pigs in herds with a respiratory disease outbreak. b Serum
R-ketoprofen concentration frequency distribution (μg/ml) in
samples (n = 79) taken on DAY 3 in ketoprofen treated finishing pigs
in herds with a respiratory disease outbreak
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effectiveness of NSAID treatment in pigs. Other re-
searchers have also suspected that comparison to refer-
ence values is complicated by a number of factors,
especially in pigs. For example, the values may not be
applicable for modern pig breeds [35].
Daily weight gain
There was no treatment effect on daily weight gain
during the treatment from DAY 0 to DAY 3. In a
previous study, no effect of ketoprofen on daily
weight gain was seen during ten days of medication,
when the drug was administered in drinking water to
pigs suffering from porcine respiratory disease
complex [15]. As already stated, the medication may
have been started too late after the onset of an acute
disease. If started earlier during the most acute phase
of the disease, the medication may have had better
possibilities to have the desired effect. As the ob-
served difference between the treatment groups in
weight gain from DAY 0 to DAY 3 was substantial, it
might be that our study again lacked sufficient power
to detect a statistically significant treatment effect.
We did observe approximately 100 g/day better aver-
age daily weight gain in the placebo group from DAY 0
to DAY 30 compared to the ketoprofen-treated group.
Although unlikely, it cannot be ruled out that the three-
day ketoprofen medication could have had a long-lasting
effect on weight gain. The issue should be investigated
further and biological explanations sought. The animals
of the placebo group were by chance slightly smaller at
the beginning of the trial than those allocated to the
ketoprofen treatment, even if the difference was not
statistically significant. We suspected that the observed
difference in daily weight gain was at least to some ex-
tent due to compensatory growth of the smaller pigs in
the placebo group. However, when this possible bio-
logical explanation was investigated further with analysis
of covariance (results not shown), this was not the case.
No perceived difficulties occurred in administering the
ketoprofen product per os mixed with regular pig feed.
Pigs in three of the herds were on restrictive feeding
where feed was available only at certain times and in
limited amounts. Probably the restricted feeding made it
easier to ascertain the intake of medicated feed, which
was offered just before the regular feeding when the pigs
were hungry. However, also in one of the herds with an
automatic feeder, the pigs consumed the medicated feed
with no problems. We did not observe treatment effect
on appetite of pigs during the treatment, while the feed
consumption increased steadily each day after DAY 0
(results not shown). In another study, NSAID treatment
has been reported to lessen the decrease in feed con-
sumption in infected pigs compared to non-medicated
animals [3].
Possible negative effects of NSAID medication
Even though NSAID medication may be helpful in in-
flammatory conditions, it should be kept in mind that
negative effects have been reported in humans following
NSAID consumption. Gastric ulceration is a well-known
side-effect of NSAIDs in human medicine [36]. In the
context of respiratory diseases, the frequency of severe
bacterial infections after exposure to NSAIDs has been
observed to be elevated in children [37]. Most studies on
ketoprofen medication in pigs do not mention the possi-
bility of negative effects. Such absence of information
should not be interpreted as absence of possible draw-
backs. However, in one study experimentally infected
pigs were treated with NSAIDs, euthanized 48 h after
the challenge and autopsied. None of the animals
showed macroscopic kidney lesions or recent gastric
ulcers [3]. In the current study, no negative effects were
observed by the farm personnel during the three days of
double-blinded medication with ketoprofen or placebo.
However, it should be admitted that minor side effects,
if present, might have gone unnoticed in the clinical set-
ting. As already discussed earlier, 3-day treatment with
ketoprofen was in our study associated with lower body
weight gain during the subsequent 30-day observation
period, but in the absence of a plausible biological ex-
planation for such an adverse effect on growth, causality
should not be assumed.
When per os medication is given to pigs in a group,
the treatment is difficult, even impossible, to restrict
only to certain animals in a group. In our study, keto-
profen (or placebo) was given to all animals in the same
pen where the representative pigs were housed as this
was considered to be the most feasible way to manage
oral medication in most commercial piggeries. It is likely
that some pigs received the medication even if they were
healthy, thus exposing them to possible negative effects
without any possible benefit. However, in case of respira-
tory diseases, the outbreak usually concerns the entire
compartment. In addition to this, some animals might
be subclinically infected and in need of medication.
Thus, we suggest that making medication decisions on a
pen-level would be accurate enough in the case of acute
infectious respiratory disease in pigs.
Ketoprofen concentrations
Medication mixed in feed of pigs comes with substantial
risks of under- or overdosing. Our study shows that the
pigs ate their ketoprofen dose voluntarily, because the
total mean serum concentration was 1.6 μg/ml at six
hours after feeding. In the ketoprofen concentration
values of individual pigs, there was only one clearly
higher (11.1 μg/ml) value. Based on this information, it
is not likely that individual animals should have con-
sumed the majority of medicated feed and possibly
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ingested significant overdoses of ketoprofen. Ketoprofen
was administered as a racemic mixture of two enantio-
mers, S- and R-ketoprofen. Only S-ketoprofen is
pharmacologically active. While both enantiomers have
approximately similar pharmacokinetic properties in
humans [38], they are handled in significantly different
fashion in several animal species, including pigs [39].
Very marked chiral conversion of R-ketoprofen to S-
ketoprofen has been observed, resulting in much faster
clearance of R-ketoprofen compared to the S-form, and
low exposure to R-ketoprofen [38, 40]. Our results are in
line with these observations. The oral bioavailability of
S-ketoprofen has been reported to be approximately
80%, when 3 mg/kg oral and intravenous doses have
been compared in pigs [39]. The concentrations of S-
ketoprofen in the serum samples collected approxi-
mately 6 h after administration of the drug mixed in feed
were close to what has previously been reported after
controlled oral administration of similar doses [39]. The
maximum concentration of ketoprofen (measured as S-
and R-ketoprofen or racemic ketoprofen) in serum is
usually recorded 1–2 h after controlled oral administra-
tion by gavage [16, 41]. It has been reported that the
mean racemic ketoprofen concentration in plasma was
at least 1 μg/ml for about 10 h after oral administration
at a dosage of 3 mg/kg in experimental settings, and this
was theoretically considered as an effective dose [41].
Low total plasma racemic ketoprofen concentrations in
pigs (0.1–2.09 μg/ml, depending on the dose given) have
anti-inflammatory effects [17]. Very low half maximal
inhibitory concentrations (IC50 0.0003–0.003 μg/ml) of
S-ketoprofen regarding inflammatory cytokine synthesis
have been reported in the goat [42]. In this study, mean
serum concentrations, derived from single blood sam-
ples, of S-ketoprofen and total racemic ketoprofen were
1.4 μg/ml and 1.55 μg/ml. Based on current, partly in-
sufficient knowledge of required therapeutic levels for
ketoprofen in pigs, the S-ketoprofen concentrations in
our study should be estimated as adequate.
Conclusions
The results indicate that ketoprofen administered in feed
at approximately 3 mg/kg body weight reduced behav-
ioural signs of sickness and had an antipyretic effect. As
there were no effects of ketoprofen on clinical signs, feed
intake or blood parameters, it can be assumed that the
effect of ketoprofen mainly affected the welfare of the
pigs, while the effect on recovery was less pronounced.
However, the medication in this study was perhaps
started only after the most severe clinical phase of the
respiratory disease was over, and this delay might have
hampered the evaluation of treatment effects. A possible
adverse effect on production cannot be excluded, as the
ketoprofen-treated animals showed lesser average
growth over the 30-day observation period than the
placebo-treated animals. Clinically significant drug
exposure was achieved by administering ketoprofen per
os mixed with regular pig feed in regular farm condi-
tions in commercial herds.
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